Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MOON LANDING WEEK IS COMING
TransCode believes it has solved one of the major challenges facing targeted therapeutic delivery to cancer
https://www.transcodetherapeutics.com/platform.html#:~:text=The%20TTX%20delivery%20system%20is,early%20kidney%20and%20liver%20clearance
111BILLION GLOBAL METASTATIC CANCER TREATMENT MARKET BY 2027 https://www.transcodetherapeutics.com/uploads/1/7/4/2/17421591/editor/focus-sidebar.png?1688673517
In 2023, Keytruda's sales grew 21% at constant exchange rates, reaching $25 billion,
IN 1969 THE FIRST MAN WALKED ON THE MOON WE LOOK FORWARD TO THE NEXT GIANT LEAP FOR THE MOON LANDING RNA BREAKTHROUGH CANCER CURE TRILLIONS ARE AT PLAY HERE
BILLIONS INCOMING BOSS$$$$$$$$$$$$$$$$$
POUR ON THE GAS AND BURN THE SHORTS WITH BREAKTHROUGH NEWS TOMORROW MORNING🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
TAKE OUT THE NEWS 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
BREAKTHROUGH NEWS TOMORROW MORNING WOULD BE A WILDFIRE 🔥🔥🔥🔥🔥🔥🔥🔥🔥
WE WANT WILDFIRE NEWS
WE WANT THE NEWS NOW SCUMBAGS
WHERES THE NEWS MR.CEO SCUMBAG
TAKE OUT THE GUNS TO $1.00
NEWS 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
OUR TIME HAS COME🔥🔥🔥🔥🔥🔥🔥🔥🔥
ATOMIC BOMB LANDING 🔥🔥🔥🔥🔥🔥
https://www.nbcnews.com/news/amp-video/mmvo217103429900
THE WHITE HOUSE IS ABOUT TO FIRE OUT THE CURE TO CANCER ON THE WORLD STAGE🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
NEWS NEEDS TO RATTLE THE AI WORLD IN EPIGENETIC
MONSTER FIND BOSS🔥🔥🔥FIRE IN ALL HOLES🔥🔥🔥
BREAKTHROUGH STATUS BOSS
HANG ON FOR LIFT-OFF BOSS
ATOMIC BOMB NEWS COMING TOMORROW MORNING
TAKE OUT THE NUCLEAR WARHEAD NEWS AND SHOCK THE AI WORLD
FOXO THE NEXT NVIDIA
SOUND ALL ALARMS SOUND ALL ALARMS,
🔥🔥ATOMIC BOMB NEWS TO THE STARS🔥🔥
🔥🔥GROUND FLOOR LIFT-OFF DECLARED BOSS🔥🔥🔥🔥
RNAZ ON THE WORLD STAGE🔥🔥🔥🔥🔥🔥
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/copper-cu-64-nodaga-ttx-mc138
TRANSCODE THERAPEUTICS WORLD LEADER 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e15072
SOUND ALL ALARMS 🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
WORLD-WIDE BREAKOUT🔥🔥🔥🔥🔥
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity.
New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate’s molecular target, miRNA-10b, in the patient’s blood. Specifically, after injection, the amount of miR-10b in the patient’s blood was significantly reduced compared to levels prior to administration of radiolabeled TTX-MC138, reaching a reduction of 66% at 24 hours following dosing. “We believe these data are important given that in several animal models, miRNA-10b inhibition by TTX-MC138 resulted in complete regressions of metastatic disease,” stated Zdravka Medarova, PhD, Chief Scientific Officer at TransCode. These data support TransCode’s belief that clinical development of TTX-MC138 has the potential for clinical benefit in patients with metastatic cancer.
In addition, the study also quantified the amount of drug candidate delivered to metastatic lesions, providing further evidence that TTX-MC138 accumulated in metastatic tumors. The increase of radioactive lesion-to-blood ratios suggests that circulating TTX-MC138 is actively taken up by the cancerous tissue.
The microdose of radiolabeled TTX-MC138 was well tolerated with no adverse events observed.
“These new data suggest that TTX-MC138 not only inhibits the miRNA-10b target but is pharmacodynamically active at a single microdose in the patient’s serum, supporting continued clinical development of TTX-MC138 for the treatment of multiple metastatic cancers in the planned Phase 1 clinical study. This could indicate a much broader therapeutic window than had previously been expected,” said Dr. Daniel Vlock, TransCode’s Chief Medical Officer.
Full data analysis is ongoing and will be included in the final study report.
A PENICILLIN MOMENT FOR CANCER TREATMENT 🔥🔥🔥🔥🔥🔥🔥🔥
BLAST OFF TO HEAVEN ALL ABOARD🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
NEW PARTNERS 🔥🔥🔥🔥🔥https://www.3i.com/about-us/
TAKE OUT THE ATOMIC BOMB NEWS AND SHOCK THE WORLD RNAZ🔥🔥🔥🔥🔥
RNAZ BACKED BY KING KONG 🔥🔥🔥🔥🔥3i has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by 3i Management, the manager and general partner of 3i. Mr. Tarlow, as the manager of 3i Management, has shared power to vote and/or dispose of the Shares beneficially owned by each of 3i and 3i Management. Mr. Tarlow does not directly own the Shares. By reason of the provisions of Rule 13d-3 of the Act, Mr. Tarlow may be deemed to beneficially own the Shares beneficially owned by 3i and 3i Management, and 3i Management may be deemed to beneficially own the Shares beneficially owned by 3i.
BIG NEWS MONDAY MORNING🔥🔥🔥🔥🔥🔥
POWERFUL NEWS FROM THE UK 🔥🔥🔥
https://www.3i.com/
SOUND ALL ALARMS SOUND ALL ALARMS BREAKTHROUGH🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
DROP THE BOMB NEWS🔥🔥🔥🔥🔥🔥🔥🔥🔥